{"entity":{"id":"nct00106431","kind":"trial","name":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)","aka":[],"tldr":"A phase 2 trial of Romidepsin in Cutaneous T-cell lymphoma, run by Celgene, completed.","summary":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) is a phase 2 interventional study registered as NCT00106431 by Celgene, with 102 participants recorded, started 2005-01-01 and reaching its primary completion in 2008-06-01. Interventions recorded: romidepsin (depsipeptide, FK228). Conditions recorded: Cutaneous T-cell Lymphoma.\n\nLinked to the drug Romidepsin because the registry names it among its interventions and Cutaneous T-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00106431","url":"https://clinicaltrials.gov/study/NCT00106431"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cutaneous-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["romidepsin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00106431","phase":"2","setting":"A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma","sponsor":"Celgene","enrolled":102,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00106431/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"}],"drug":[{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}